Innate Pharma Announces Abstracts Selected for ESMO Congress 2023
16 Outubro 2023 - 2:00AM
Business Wire
- Sanofi’s ongoing SAR’579/IPH6101 Phase 1/2 trial in
hematologic malignancies selected for oral presentation
- Presentations under the AstraZeneca collaboration include an
IPH5201 early lung cancer Trial in Progress poster and monalizumab
SCCHN updates
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)
(“Innate” or the “Company”) today announced that the
following presentations will be presented at the European Society
for Medical Oncology (ESMO) Congress 2023, taking place October
20-24 in Madrid, Spain.
Abstract details:
SAR’579 / IPH6101 (from a Joint
Research Collaboration with Sanofi)
Presentation Number: 823O
Presentation Title: Preliminary Pharmacokinetics (PK) and
Pharmacodynamic (PD) Analysis of the CD123 NK Cell Engager (NKCE)
SAR443579 in Patients (pts) with Relapsed or Refractory Acute
Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia
(B-ALL) or High Risk-Myelodysplasia (HR-MDS) Speaker: Mojca
Jongen-Lavrencic (Rotterdam, Netherlands) Session Type/Title:
Oral Session: Proffered Paper Session / Hematologic
Malignancies Session Date and Time: Sun, 22.10.2023 16:30 –
18:00
IPH5201 (AstraZeneca
collaboration)
Abstract: 1290TiP Abstract
Title: A Phase II multicenter, open label, non-randomized study
of neoadjuvant and adjuvant treatment with IPH5201 and durvalumab
in patients with resectable, early-stage (II to IIIA) non-small
cell lung cancer (MATISSE) Speaker: Fabrice Barlesi
(Villejuif, France) Session Type/Title: Poster Session:
NSCLC, early stage Onsite Poster display date: Sat,
21.10.2023
Monalizumab (AstraZeneca collaboration;
ISS)
Abstract: 935P Abstract Title:
A phase II study of monalizumab and durvalumab in patients with
recurrent/metastatic (RM) squamous cell carcinoma of the head and
neck (SCCHN): results of the I2 cohort of the EORTC-HNCG-1559 trial
(UPSTREAM). Speaker: Rachel Galot (Woluwe-Saint-Lambert,
Belgium) Session Type/Title: Poster Session: Head and neck
cancers, excl. thyroid Onsite Poster display date: Sun,
22.10.2023
Monalizumab (AstraZeneca
collaboration)
Presentation Number: 854O
Presentation Title: INTERLINK-1: Phase 3 study of cetuximab
(CTX) ± monalizumab (M) in participants (pts) with
recurrent/metastatic head and neck squamous cell carcinoma (R/M
HNSCC) with disease progression on/after platinum chemotherapy (CT)
and previously treated with an immune checkpoint inhibitor (ICI)
Speaker: Jérôme Fayette (Lyon, France) Session
Type/Title: Oral Session: Proffered Paper Session / Head
and neck cancer Session Date and Time: Mon, 23.10.2023 08:30
– 10:00
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology
company developing immunotherapies for cancer patients. Its
innovative approach aims to harness the innate immune system
through therapeutic antibodies and its ANKET®
(Antibody-based NK cell Engager
Therapeutics) proprietary platform.
Innate’s portfolio includes lead proprietary program lacutamab,
developed in advanced form of cutaneous T cell lymphomas and
peripheral T cell lymphomas, monalizumab developed with AstraZeneca
in non-small cell lung cancer, as well as ANKET® multi-specific NK
cell engagers to address multiple tumor types.
Innate Pharma is a trusted partner to biopharmaceutical
companies such as Sanofi and AstraZeneca, as well as leading
research institutions, to accelerate innovation, research and
development for the benefit of patients.
Headquartered in Marseille, France with a US office in
Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq
in the US.
Learn more about Innate Pharma at www.innate-pharma.com and
follow us on Twitter and LinkedIn.
Information about Innate Pharma shares
ISIN code Ticker
code LEI
FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk
factors
This press release contains certain forward-looking statements,
including those within the meaning of the Private Securities
Litigation Reform Act of 1995. The use of certain words, including
“believe,” “potential,” “expect” and “will” and similar
expressions, is intended to identify forward-looking statements.
Although the company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s commercialization efforts and the Company’s continued
ability to raise capital to fund its development. For an additional
discussion of risks and uncertainties which could cause the
company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque")
section of the Universal Registration Document filed with the
French Financial Markets Authority (“AMF”), which is available on
the AMF website http://www.amf-france.org or on Innate Pharma’s
website, and public filings and reports filed with the U.S.
Securities and Exchange Commission (“SEC”), including the Company’s
Annual Report on Form 20-F for the year ended December 31, 2022,
and subsequent filings and reports filed with the AMF or SEC, or
otherwise made public, by the Company.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231015197980/en/
Investors
Innate Pharma Henry
Wheeler Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
Media Relations
NewCap Arthur Rouillé Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu
Innate Pharma (EU:IPH)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Innate Pharma (EU:IPH)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024